Artur Figueiredo Delgado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Artur Figueiredo Delgado has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Werther Brunow de Carvalho
Universidade de São Paulo, Brazil
18 shared publications - Clovis Artur Silva
Instituto da Criança e do Adolescente, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
7 shared publications - Isadora Souza Rodriguez
Pediatric Intensive Care Unit Instituto da Criança e do Adolescente, Hospital das Clínicas da Universidade de São Paulo São Paulo Brazil
6 shared publications - Cíntia Johnston
Universidade Federal de São Paulo, Brazil
5 shared publications - Uenis Tannuri
Universidade de São Paulo, Brazil
5 shared publications - Patrícia Zamberlan
Universidade de São Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 26 March 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (1) , 87-95
Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk
Objectives: Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains poorly characterized. We aimed to characterize clinical features, management patterns, and surgical outcomes of pediatric U‐SBCD in Brazil, establishing IBD baseline for future regional comparisons in LMIC setting. Methods: This multicenter retrospective study analyzed 124 pediatric Crohn′s disease (CD) patients (diagnosed < 18 years) from six Brazilian centers according to revised PORTO‐European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria. Patients with U‐SBCD (Paris L4a/L4b, n = 39) were compared to non‐SBCD (L1/L2/L3). Univariate and multivariable analyses assessed demographics, diagnostic delay, disease behavior, growth impairment, and therapeutic outcomes over 18 months follow‐up. The population comprised predominantly African–Brazilian admixture. Results: U‐SBCD patients presented at older age (median 14 vs. 12 years; p = 0.001) with greater height impairment ( p = 0.010) and lower body mass index (BMI)/age z ‐scores (−1.14 vs. −0.44; p = 0.029). Severe weight loss ( z ‐score < −2) conferred 8.3‐fold increased U‐SBCD odds (95% confidence interval [CI]: 2.17–31.66; p = 0.002). Each year of diagnostic delay increased U‐SBCD odds by 22% (95% CI: 1.06–1.39; p = 0.004). U‐SBCD patients required more biologic therapy (97% vs. 75%; p = 0.003) with higher treatment escalation rates (31.6% vs. 21.2%; p = 0.004). Multivariate analysis confirmed U‐SBCD as an independent three‐fold predictor of surgery (OR 3.02; 95% CI: 1.02–8.94; p = 0.046). A 9‐year‐old girl with U‐SBCD died perioperatively. Psychiatric symptoms affected 30% of both groups. Conclusion: In LMIC settings, strengthening medical education is essential to improve early recognition of U‐SBCD and prevent progression to irreversible complications. Notably, the phenotypic pattern observed in our study more closely resembled that reported in Asian pediatric patients than Caucasian cohorts.
- 26 March 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (1) , 87-95
Open AccessUpper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk
Objectives: Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains poorly characterized. We aimed to characterize clinical features, management patterns, and surgical outcomes of pediatric U‐SBCD in Brazil, establishing IBD baseline for future regional comparisons in LMIC setting. Methods: This multicenter retrospective study analyzed 124 pediatric Crohn′s disease (CD) patients (diagnosed < 18 years) from six Brazilian centers according to revised PORTO‐European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria. Patients with U‐SBCD (Paris L4a/L4b, n = 39) were compared to non‐SBCD (L1/L2/L3). Univariate and multivariable analyses assessed demographics, diagnostic delay, disease behavior, growth impairment, and therapeutic outcomes over 18 months follow‐up. The population comprised predominantly African–Brazilian admixture. Results: U‐SBCD patients presented at older age (median 14 vs. 12 years; p = 0.001) with greater height impairment ( p = 0.010) and lower body mass index (BMI)/age z ‐scores (−1.14 vs. −0.44; p = 0.029). Severe weight loss ( z ‐score < −2) conferred 8.3‐fold increased U‐SBCD odds (95% confidence interval [CI]: 2.17–31.66; p = 0.002). Each year of diagnostic delay increased U‐SBCD odds by 22% (95% CI: 1.06–1.39; p = 0.004). U‐SBCD patients required more biologic therapy (97% vs. 75%; p = 0.003) with higher treatment escalation rates (31.6% vs. 21.2%; p = 0.004). Multivariate analysis confirmed U‐SBCD as an independent three‐fold predictor of surgery (OR 3.02; 95% CI: 1.02–8.94; p = 0.046). A 9‐year‐old girl with U‐SBCD died perioperatively. Psychiatric symptoms affected 30% of both groups. Conclusion: In LMIC settings, strengthening medical education is essential to improve early recognition of U‐SBCD and prevent progression to irreversible complications. Notably, the phenotypic pattern observed in our study more closely resembled that reported in Asian pediatric patients than Caucasian cohorts.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 44, e2025246
NutriRisKids-ICU: Development and content validation of a nutritional risk screening tool for critically ill children and adolescents
Objective: The aim of this study was to develop and validate the content of a nutritional risk screening tool for critically ill children and adolescents in pediatric intensive care units (PICUs). Methods: Care-convergent study for the development and content validation of an instrument for assessing nutritional risk in children admitted to the PICU. The initial development was based on a literature review and the clinical experience of the authors. Content validation was conducted using the Delphi technique in two successive rounds with intentionally selected experts, each with a minimum of 5 years of experience in pediatric intensive nutritional therapy (NT). Consensus analysis was performed using the content validity index (CVI), with minimum values of 0.70 for individual items and 0.90 for the overall instrument. Results: Validation occurred in two rounds. In the first round, 18 experts suggested adjustments, and the revised version was reassessed by 12 experts in the second round. The final tool achieved an overall CVI of 0.958. The validated version included age subgroups, presence of chronic diseases, length of prior hospitalization, subjective impression of malnutrition risk, type of NT at admission, and C-reactive protein (CRP) levels. Conclusions: The nutritional risk screening tool for critically ill pediatric patients, named NutriRisKids-ICU, was developed, and its content was validated by expert consensus. The tool combines theoretical evidence and clinical expertise, showing potential for application in PICUs. However, further studies are needed to assess its applicability, sensitivity, and specificity.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 44, e2025246
Open AccessNutriRisKids-ICU: Development and content validation of a nutritional risk screening tool for critically ill children and adolescents
Objective: The aim of this study was to develop and validate the content of a nutritional risk screening tool for critically ill children and adolescents in pediatric intensive care units (PICUs). Methods: Care-convergent study for the development and content validation of an instrument for assessing nutritional risk in children admitted to the PICU. The initial development was based on a literature review and the clinical experience of the authors. Content validation was conducted using the Delphi technique in two successive rounds with intentionally selected experts, each with a minimum of 5 years of experience in pediatric intensive nutritional therapy (NT). Consensus analysis was performed using the content validity index (CVI), with minimum values of 0.70 for individual items and 0.90 for the overall instrument. Results: Validation occurred in two rounds. In the first round, 18 experts suggested adjustments, and the revised version was reassessed by 12 experts in the second round. The final tool achieved an overall CVI of 0.958. The validated version included age subgroups, presence of chronic diseases, length of prior hospitalization, subjective impression of malnutrition risk, type of NT at admission, and C-reactive protein (CRP) levels. Conclusions: The nutritional risk screening tool for critically ill pediatric patients, named NutriRisKids-ICU, was developed, and its content was validated by expert consensus. The tool combines theoretical evidence and clinical expertise, showing potential for application in PICUs. However, further studies are needed to assess its applicability, sensitivity, and specificity.
- 3 November 2022
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 23 (Supplement)
OP009 [Other]: MALNUTRITION AND OBESITY PREVALENCE IN CRITICALLY ILL LATIN AMERICAN CHILDREN: A PRELIMINARY REPORT OF THE NUTRIPIC STUDY
- 3 November 2022
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 23 (Supplement)
OP009 [Other]: MALNUTRITION AND OBESITY PREVALENCE IN CRITICALLY ILL LATIN AMERICAN CHILDREN: A PRELIMINARY REPORT OF THE NUTRIPIC STUDY
- Open Access
- 9 April 2022
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (6) , 607-613
Development of a prognostic model for pediatric acute liver failure in a Brazilian center
- 9 April 2022
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (6) , 607-613
Open AccessDevelopment of a prognostic model for pediatric acute liver failure in a Brazilian center
- 28 February 2022
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 37 (2) , 393-401
Increased nutrition risk at admission is associated with longer hospitalization in children and adolescents with COVID‐19
Background: We investigated the association of nutritional risk and inflammatory marker level with length of stay (LOS) in children and adolescents hospitalized for COVID‐19 infection in two pediatric teaching hospitals in a developing country.Methods: This was a cross‐sectional analytical retrospective study performed in two pediatric hospitals. We included the data from all children and adolescents who were hospitalized with a SARS‐CoV‐2 infection between March and December 2020. Demographic, anthropometric, clinical, and laboratory data were extracted from electronic medical records. Nutritional risk was assessed according to the STRONGkids tool within 24 hours of admission and was categorized into two levels: ≥4 (high risk) and Utest, respectively. The association of nutritional risk and inflammatory markers with LOS was estimated using the Kaplan–Meier method and log‐rank test. Cox proportional‐hazard and linear regression models were performed, and adjusted for sex, age, and respiratory symptoms.Results: From a total of 73 patients, 20 (27.4%) had a STRONGkids score ≥4 at admission, which was associated with a longer LOS even after adjusting (β= 12.30; 1.74–22.9 95% CI;P = 0.023). The same association was observed between LOS and all laboratory markers except for D‐dimer.Conclusion: Among children and adolescents with COVID‐19, a STRONGkids score ≥4 at admission, lower values of albumin, lymphocytes, and hemoglobin, and higher CRP values were associated with longer LOS.
- 28 February 2022
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 37 (2) , 393-401
Increased nutrition risk at admission is associated with longer hospitalization in children and adolescents with COVID‐19
Background: We investigated the association of nutritional risk and inflammatory marker level with length of stay (LOS) in children and adolescents hospitalized for COVID‐19 infection in two pediatric teaching hospitals in a developing country.Methods: This was a cross‐sectional analytical retrospective study performed in two pediatric hospitals. We included the data from all children and adolescents who were hospitalized with a SARS‐CoV‐2 infection between March and December 2020. Demographic, anthropometric, clinical, and laboratory data were extracted from electronic medical records. Nutritional risk was assessed according to the STRONGkids tool within 24 hours of admission and was categorized into two levels: ≥4 (high risk) and Utest, respectively. The association of nutritional risk and inflammatory markers with LOS was estimated using the Kaplan–Meier method and log‐rank test. Cox proportional‐hazard and linear regression models were performed, and adjusted for sex, age, and respiratory symptoms.Results: From a total of 73 patients, 20 (27.4%) had a STRONGkids score ≥4 at admission, which was associated with a longer LOS even after adjusting (β= 12.30; 1.74–22.9 95% CI;P = 0.023). The same association was observed between LOS and all laboratory markers except for D‐dimer.Conclusion: Among children and adolescents with COVID‐19, a STRONGkids score ≥4 at admission, lower values of albumin, lymphocytes, and hemoglobin, and higher CRP values were associated with longer LOS.
- Open Access
Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital
To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19.
Open AccessDifferences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital
To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19.
- Open Access
- 25 November 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eRC6048
COVID-19 and coinfection with Clostridioides ( Clostridium ) difficile in an infant with gastrointestinal manifestation
We report the clinical case of an infant with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with gastrointestinal signs and symptoms, predominantly vomiting. The patient also had colic, poor feeding, mild diarrhea and mild rhinorrhea without fever. The child had evidence of altered coagulation, increased interleukin 10, moderate dehydration and she was admitted to the pediatric intensive care unit. Simultaneously, the patient was diagnosed as Clostridioides difficile infection, which possibly may have facilitated the persistence of SARS-CoV-2 in [...] ABSTRACT We report the clinical case of an infant with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with gastrointestinal signs and symptoms, predominantly vomiting. The patient also had colic, poor feeding, mild diarrhea and mild rhinorrhea without fever. The child had evidence of altered coagulation, increased interleukin 10, moderate dehydration and she was admitted to the pediatric intensive care unit. Simultaneously, the patient was diagnosed as Clostridioides difficile infection, which possibly may have facilitated the persistence of SARS-CoV-2 in
- 25 November 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eRC6048
Open AccessCOVID-19 and coinfection with Clostridioides ( Clostridium ) difficile in an infant with gastrointestinal manifestation
We report the clinical case of an infant with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with gastrointestinal signs and symptoms, predominantly vomiting. The patient also had colic, poor feeding, mild diarrhea and mild rhinorrhea without fever. The child had evidence of altered coagulation, increased interleukin 10, moderate dehydration and she was admitted to the pediatric intensive care unit. Simultaneously, the patient was diagnosed as Clostridioides difficile infection, which possibly may have facilitated the persistence of SARS-CoV-2 in [...] ABSTRACT We report the clinical case of an infant with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with gastrointestinal signs and symptoms, predominantly vomiting. The patient also had colic, poor feeding, mild diarrhea and mild rhinorrhea without fever. The child had evidence of altered coagulation, increased interleukin 10, moderate dehydration and she was admitted to the pediatric intensive care unit. Simultaneously, the patient was diagnosed as Clostridioides difficile infection, which possibly may have facilitated the persistence of SARS-CoV-2 in
- Open Access
- 1 August 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (8) , 1016-1017
Burnout in pediatric critical care medicine: more challenging days during the COVID-19 pandemic
- 1 August 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (8) , 1016-1017
Open AccessBurnout in pediatric critical care medicine: more challenging days during the COVID-19 pandemic